Valvular heart disease associated with taking low-dose pergolide for restless legs syndrome
Author(s) -
A. Worthington,
Liza Thomas
Publication year - 2008
Publication title -
european journal of echocardiography
Language(s) - English
Resource type - Journals
eISSN - 1525-2167
pISSN - 1532-2114
DOI - 10.1093/ejechocard/jen191
Subject(s) - pergolide , medicine , valvular heart disease , cardiology , calcification , ropinirole , disease , surgery , dopamine agonist , dopamine , parkinson's disease , dopaminergic , levodopa
A 49-year-old female took low-dose pergolide (625 microg daily) for approx. 5 years (approximately cumulative dose 1.140 g/5 years) for the treatment of restless legs syndrome. She developed moderate to severe mitral and aortic valve insufficiency, requiring semi-urgent double-valve replacement. The initial diagnosis of rheumatic valve disease was refuted on histological examination of the valves due to the lack of typical calcification and neovascularization. Valvular heart disease is associated with the use of dopamine agonists for the treatment of Parkinson's disease and obesity, typically at much higher doses.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom